Sanofi (SNY)
| Market Cap | 113.21B -11.7% |
| Revenue (ttm) | 54.85B +5.5% |
| Net Income | 9.17B +40.5% |
| EPS | 7.48 +43.6% |
| Shares Out | 1.21B |
| PE Ratio | 12.34 |
| Forward PE | 9.38 |
| Dividend | $1.60 (3.42%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 2,918,176 |
| Open | 47.37 |
| Previous Close | 47.53 |
| Day's Range | 46.72 - 47.50 |
| 52-Week Range | 43.32 - 55.73 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 58.00 (+23.99%) |
| Earnings Date | Apr 23, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $58.0, which is an increase of 23.99% from the latest price.
News
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million...
Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments
Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments
Q1 2026 Sanofi SA Earnings Call Transcript
Q1 2026 Sanofi SA Earnings Call Transcript
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
French drugmaker Sanofi SA (NASDAQ: SNY) and its partner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Wednesday secured U.S. Food and Drug Administration (FDA) approval for Dupixent (dupilumab) ...
Sanofi Leans On Dupixent For First-Quarter Beat A Week Ahead Of New CEO
Sanofi stock jumped early Thursday on strong first-quarter sales and earnings, with new CEO Belen Garijo set to take the reins next week.
Sanofi Faces Revenue Replacement Challenge After Dupixent Patent Expiry
Sanofi Faces Revenue Replacement Challenge After Dupixent Patent Expiry
Sanofi (SNY) Exceeds Q1 Expectations with Robust Sales and EPS Growth
Sanofi (SNY) Exceeds Q1 Expectations with Robust Sales and EPS Growth
Sanofi (SNY) and Regeneron (REGN) Gain U.S. Approval for Dupixent in Young Children
Sanofi (SNY) and Regeneron (REGN) Gain U.S. Approval for Dupixent in Young Children
Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales Growth
Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales Growth
Sanofi Posts Higher Sales Amid Leadership Transition
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
Sanofi Q1 Business Net Income Rises; Reiterates 2026 Guidance
(RTTNews) - Sanofi (SNY, SAN.PA) reported that its first quarter net income from continuing operations declined to 1.59 billion euros from 1.72 billion euros, prior year. Basic earnings per share from...
Sanofi's first quarter earnings edges past estimates ahead of CEO change
French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.
Sanofi (SNY) Receives FDA Approval for Dupixent in Young Patients
Sanofi (SNY) Receives FDA Approval for Dupixent in Young Patients
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision
The U.S. Food and Drug Administration (FDA) on Wednesday delayed its decision on Sanofi SA’ s (NASDAQ: SNY) subcutaneous Sarclisa formulation while separately broadening the eligible patient populati...
Sanofi's Tzield Wins Expanded FDA Approval For Young Children At Risk Of Type 1 Diabetes
(RTTNews) - Sanofi (SNY) announced that the U.S. FDA has approved Tzield for use in children as young as one year old with stage 2 type 1 diabetes, expanding access to a therapy that can delay the ons...
Sanofi Says FDA Extends Review Of Sarclisa SC By Up To Three Months
PARIS (dpa-AFX) - Sanofi SA (SNY) on Wednesday said the U.S. Food and Drug Administration has extended by up to three months the timeline to review Sarclisa subcutaneous (SC) formulation in combin...
Sanofi (SNY) Gains FDA Approval for Tzield to Treat Young Diabetes Patients
Sanofi (SNY) Gains FDA Approval for Tzield to Treat Young Diabetes Patients
Sanofi Wins FDA Nod To Expand Use Of Type 1 Diabetes Drug In Younger Children
PARIS (dpa-AFX) - Sanofi SA (SNY) on Wednesday said the U.S. Food and Drug Administration has approved Tzield to expand its indication from patients aged eight years and older to those as young as...
Sanofi: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the targe...
Sanofi: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of...
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of st...
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target a...
Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study
(RTTNews) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest mRNA vaccine, mN...